Today, we announced the completion of our acquisition of EyeBio, further diversifying and strengthening our late-stage pipeline with the addition of novel candidates targeting certain retinal diseases. Read more: http://merck.us/3S0Y4rS
EyeBio
Biotechnology Research
Developing a new generation of therapies to protect, restore, and improve vision
About us
EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
- Website
-
https://eyebiotech.com/
External link for EyeBio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2021
- Specialties
- ophthalmology, biopharmaceuticals, and biotechnology
Locations
-
Primary
Get directions
London, GB
-
Get directions
New York, US
Employees at EyeBio
Updates
-
Today, we announced an agreement to be acquired by Merck, known as MSD outside the United States and Canada. The acquisition allows our team to continue advancing our innovative pipeline, with the benefit of infrastructure, resources, and support from Merck. We are excited to move into this next chapter, as we pursue potential treatments for retinal diseases like #wetamd and #diabeticmacularedema. Read more here: https://bit.ly/3KnPAqC #ophthalmology #eyedisease #mergersandacquisitions #visionloss #biotech #lifesciences #biopharma
-
-
We are thrilled to share today’s news that EyeBio has been acquired by Merck/MSD. Learn more at our website, eyebiotech.com, and below.
Today, we announced an agreement to acquire EyeBio, a clinical-stage ophthalmology-focused biotech company, advancing novel investigational candidates for retinal diseases, including #diabeticmacularedema. This acquisition augments our pipeline and expands our research presence in #ophthalmology. https://msd.gl/3Vu84MF
-
-
Today, we announced the presentation of Week 12 data from the first-in-human Phase 1b/2a AMARONE trial of Restoret in patients with treatment-naïve diabetic macular edema (DME) and treatment-naïve neovascular age-related macular degeneration (NVAMD). Based on the data, Restoret was well-tolerated in patients with DME and NVAMD, and the results established proof of concept with strong visual and anatomic outcomes. Read more here: https://bit.ly/49w46Hb #ophthalmology #eyedisease #visionloss #blindness #biotech #biotechnology #pharma #pharmaceutical #lifesciences #biopharma
-
-
Today we announced the successful close of an extension to our Series A financing with an additional $65 million. This brings the total raised to date to $130 million, doubling the size of our original Series A. The funding will accelerate our clinical development program and give us the ability to further build out our innovative retina pipeline. Read more here: https://bit.ly/47e4DNg #ophthalmology #eyedisease #visionloss #blindness #biotech #biotechnology #pharma #pharmaceutical #lifesciences #biopharma
-
-
Our co-founder and chief scientific officer, Dr. Tony Adamis, spoke with The Ophthalmologist to discuss how our lead asset, Restoret, may hold the key to potentially breaking through the efficacy ceiling reached with the anti-VEGF standard of care by addressing the Wnt pathway. He also shared details about the company’s Phase 1b/2 AMARONE clinical trial and how it will assess the safety and preliminary efficacy of Restoret for improving the visual acuity of patients with neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME), as well as other retinal diseases. Read the full interview here: http://bit.ly/3Efwyjb
-
EyeBio reposted this
SV’s 21st drug approval! Izervay, developed by SV portfolio company Iveric Bio, An Astellas Company which was led by SV Venture Partner David Guyer (and now CEO of SV created EyeBio), has received FDA approval making it the only approved treatment for geographic atrophy with a statistically significant reduction in the rate of disease progression at the 12-month primary endpoint across two Phase 3 clinical trials. Geographic atrophy is a disease which has a devastating impact on patients' lives and can lead to irreversible vision loss. #drugapproval #Izervay https://lnkd.in/gGsT6ra5
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
prnewswire.com